Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

Por Ebdrup, Bjørn H, Knop, Filip K, Ishøy, Pelle L, Rostrup, Egill, Fagerlund, Birgitte, Lublin, Henrik, Glenthøj, Birte
Publicado em 2012

Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial

Por Ishøy, Pelle L., Knop, Filip K., Broberg, Brian V., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Holst, Jens J., Glenthøj, Birte Y., Ebdrup, Bjørn H.
Publicado no Diabetes Obes Metab (2016)

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded inter...

Por Ishøy, Pelle L, Knop, Filip K, Broberg, Brian V, Baandrup, Lone, Fagerlund, Birgitte, Jørgensen, Niklas R, Andersen, Ulrik B, Rostrup, Egill, Glenthøj, Birte Y, Ebdrup, Bjørn H
Publicado em 2014